These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 19199360)

  • 1. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency.
    Mikkelsen T; Brodie C; Finniss S; Berens ME; Rennert JL; Nelson K; Lemke N; Brown SL; Hahn D; Neuteboom B; Goodman SL
    Int J Cancer; 2009 Jun; 124(11):2719-27. PubMed ID: 19199360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cilengitide targets pediatric glioma and neuroblastoma cells through cell detachment and anoikis induction.
    Leblond P; Dewitte A; Le Tinier F; Bal-Mahieu C; Baroncini M; Sarrazin T; Lartigau E; Lansiaux A; Meignan S
    Anticancer Drugs; 2013 Sep; 24(8):818-25. PubMed ID: 23728220
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts.
    Burke PA; DeNardo SJ; Miers LA; Lamborn KR; Matzku S; DeNardo GL
    Cancer Res; 2002 Aug; 62(15):4263-72. PubMed ID: 12154028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cilengitide modulates attachment and viability of human glioma cells, but not sensitivity to irradiation or temozolomide in vitro.
    Maurer GD; Tritschler I; Adams B; Tabatabai G; Wick W; Stupp R; Weller M
    Neuro Oncol; 2009 Dec; 11(6):747-56. PubMed ID: 19221171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting αvβ3 and αvβ5 integrins inhibits pulmonary metastasis in an intratibial xenograft osteosarcoma mouse model.
    Gvozdenovic A; Boro A; Meier D; Bode-Lesniewska B; Born W; Muff R; Fuchs B
    Oncotarget; 2016 Aug; 7(34):55141-55154. PubMed ID: 27409827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cilengitide inhibits attachment and invasion of malignant pleural mesothelioma cells through antagonism of integrins αvβ3 and αvβ5.
    Cheng NC; van Zandwijk N; Reid G
    PLoS One; 2014; 9(3):e90374. PubMed ID: 24595274
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin alpha v beta 3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models.
    Albert JM; Cao C; Geng L; Leavitt L; Hallahan DE; Lu B
    Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1536-43. PubMed ID: 16863930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cilengitide induces cellular detachment and apoptosis in endothelial and glioma cells mediated by inhibition of FAK/src/AKT pathway.
    Oliveira-Ferrer L; Hauschild J; Fiedler W; Bokemeyer C; Nippgen J; Celik I; Schuch G
    J Exp Clin Cancer Res; 2008 Dec; 27(1):86. PubMed ID: 19114005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
    Alghisi GC; Ponsonnet L; Rüegg C
    PLoS One; 2009; 4(2):e4449. PubMed ID: 19212436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and disposition of the αv-integrin ß3/ß5 receptor antagonist cilengitide, a cyclic polypeptide, in humans.
    Becker A; von Richter O; Kovar A; Scheible H; van Lier JJ; Johne A
    J Clin Pharmacol; 2015 Jul; 55(7):815-24. PubMed ID: 25683324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual αvβ3 and αvβ5 blockade attenuates fibrotic and vascular alterations in a murine model of systemic sclerosis.
    Bagnato GL; Irrera N; Pizzino G; Santoro D; Roberts WN; Bagnato G; Pallio G; Vaccaro M; Squadrito F; Saitta A; Altavilla D; Bitto A
    Clin Sci (Lond); 2018 Jan; 132(2):231-242. PubMed ID: 29237724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The inhibitor of integrins Cilengitide: a new active drug in neuro-oncology].
    Leblond P; Meignan S; Le Tinier F; Bethe U; Lansiaux A
    Bull Cancer; 2011 Oct; 98(9):1083-90. PubMed ID: 21914576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The αVβ3/αVβ5 integrin inhibitor cilengitide augments tumor response to melphalan isolated limb perfusion in a sarcoma model.
    Ten Hagen TL; Seynhaeve AL; de Wiel-Ambagtsheer Ga; de Bruijn EA; van Tiel ST; Ruegg C; Meyring M; Grell M; Goodman SL; Eggermont AM
    Int J Cancer; 2013 Jun; 132(11):2694-704. PubMed ID: 23152080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cilengitide restrains the osteoclast-like bone resorbing activity of myeloma plasma cells.
    Tucci M; Stucci S; Felici C; Cafforio P; Resta L; Rossi R; Silvestris F
    Br J Haematol; 2016 Apr; 173(1):59-69. PubMed ID: 26728969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
    Anderson HJ; Galileo DS
    Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cilengitide, an αvβ3-integrin inhibitor, enhances the efficacy of anti-programmed cell death-1 therapy in a murine melanoma model.
    Pan X; Yi M; Liu C; Jin Y; Liu B; Hu G; Yuan X
    Bioengineered; 2022 Feb; 13(2):4557-4572. PubMed ID: 35142593
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cilengitide inhibits metastatic bone colonization in a nude rat model.
    Bretschi M; Merz M; Komljenovic D; Berger MR; Semmler W; Bäuerle T
    Oncol Rep; 2011 Oct; 26(4):843-51. PubMed ID: 21725616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cilengitide in newly diagnosed glioblastoma: biomarker expression and outcome.
    Weller M; Nabors LB; Gorlia T; Leske H; Rushing E; Bady P; Hicking C; Perry J; Hong YK; Roth P; Wick W; Goodman SL; Hegi ME; Picard M; Moch H; Straub J; Stupp R
    Oncotarget; 2016 Mar; 7(12):15018-32. PubMed ID: 26918452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The integrin inhibitor cilengitide affects meningioma cell motility and invasion.
    Wilisch-Neumann A; Kliese N; Pachow D; Schneider T; Warnke JP; Braunsdorf WE; Böhmer FD; Hass P; Pasemann D; Helbing C; Kirches E; Mawrin C
    Clin Cancer Res; 2013 Oct; 19(19):5402-12. PubMed ID: 23948974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro study of combined cilengitide and radiation treatment in breast cancer cell lines.
    Lautenschlaeger T; Perry J; Peereboom D; Li B; Ibrahim A; Huebner A; Meng W; White J; Chakravarti A
    Radiat Oncol; 2013 Oct; 8():246. PubMed ID: 24153102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.